FREISING-WEIHENSTEPHAN, Germany, May 17 /PRNewswire/ -- Pieris Proteolab AG announced today the appointment with immediate effect of Evert Kuppers (37) as its new Chief Executive Officer. Mr Kuppers joins Pieris from IDEA AG, where he was Vice President and Head of Business Development. He played a pivotal role in the company’s corporate development by securing the Johnson & Johnson partnership for its lead late stage clinical product. Prior to IDEA he worked in London, United Kingdom, for the global pharmaceutical / health care practice of AT Kearney, a management consultancy firm. Mr Kuppers acquired extensive operational experience during his four year tenure at BASF Pharma (now Abbott Labs.) for whom he also spent two years in Buenos Aires, Argentina, facilitating the establishment of its local businesses.
Mr Kuppers has a background in advanced biomedical sciences, having obtained extensive molecular biology research experience in the USA and The Netherlands, and an MBA degree from the Rotterdam School of Management, Erasmus University Rotterdam, The Netherlands.
“We are extremely pleased that Evert Kuppers has accepted this position at Pieris” commented Dr Hans Kupper, Chairman of the Supervisory Board. “The company is in an exciting phase, where especially the experiences and hands-on skills of Mr Kuppers are seen as very complementary.”
Evert Kuppers, as appointed CEO, commented: “I am delighted to join Pieris at such an interesting time. The industry is increasingly appreciating the uniqueness of Pieris’ proprietary ANTICALIN® technology, as illustrated by our ongoing partnership with Syngenta and our recently signed collaboration with GE Healthcare”.
For further information, please contact:
PIERIS Proteolab AG Evert Kuppers, Chief Executive Officer, Phone: +49-(0)-8161-1411-400
Notes to Editors: About Pieris Proteolab AG Pieris, located just outside of Munich, Germany, is a biopharmaceutical company focused on developing innovative ANTICALIN® therapies for oncology, immunology and cardiovascular diseases. Exploiting extensive know-how in protein engineering as part of a broad intellectual property portfolio, the Company applies a balanced risk business model to the development of its ANTICALIN® candidates. Recognising the enormous market potential of protein-based drugs, Pieris is creating the infrastructure of a drug discovery and development company and expects to submit its first therapeutic ANTICALIN® IND in 2007.
For further corporate information please visit http://www.pieris.biz
ANTICALIN, ANTICALINS, PIERIS Proteolab, and the company’s logo are registered trademarks of PIERIS Proteolab AG.
Pressekontakt:
PIERIS Proteolab AG Evert Kuppers, Chief Executive Officer, Phone: +49-(0)-8161-1411-400
Source: Pieris ProteoLab AG
